ENFN - Enfusion, Inc.

NYSE - NYSE Delayed Price. Currency in USD

8.61

+0.21

(+2.50%)

At close: 04:00PM EDT

8.61

0.00

(0.00%)

After hours:

04:15PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Commodity Channel Index

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	8.40
Open	8.44
Bid	8.33 x 1100
Ask	8.59 x 1300
Day's Range	8.33 - 8.71
52 Week Range	7.37 - 16.76
Volume	330,967
Avg. Volume	382,014

Market Cap	646.502M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	215.25
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-50% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ENFN

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

News

Simply Wall St.
Is The Market Rewarding Enfusion, Inc. (NYSE:ENFN) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
With its stock down 23% over the past three months, it is easy to disregard Enfusion (NYSE:ENFN). It seems that the...
Thomson Reuters StreetEvents
Q1 2023 Enfusion Inc Earnings Call
Q1 2023 Enfusion Inc Earnings Call
Zacks
Enfusion, Inc. (ENFN) Q1 Earnings Meet Estimates
Enfusion, Inc. (ENFN) delivered earnings and revenue surprises of 0% and 2.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Enfusion and Granite Construction have been highlighted as Zacks Bull and Bear of the Day
Enfusion and Granite Construction are part of the Zacks Bull and Bear of the Day article.
Zacks
Bull Of The Day: Enfusion (ENFN)
This stock has some good historical and projected topline growth.
Zacks
BCE's Q1 Earnings Beat Estimates, Revenues Increase Y/Y
BCE's first-quarter performance benefits from solid residential Internet growth and higher Bell CTS sales.
Zacks
DoorDash (DASH) Reports Q1 Loss, Beats Revenue Estimates
DoorDash's (DASH) first-quarter 2023 results reflect higher costs despite a significant rise in total orders.
Zacks
BILL Holdings (BILL) Q3 Earnings Top Estimates, Revenues Up Y/Y
BILL Holdings' (BILL) third-quarter fiscal 2023 results reflect solid growth in its standalone BILL Platform and Divvy spend management solution.
Zacks
Shopify (SHOP) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Shopify's (SHOP) first-quarter 2023 results benefit from growth in merchant solutions revenues and an expanding merchant base.
Zacks
Microchip (MCHP) Q4 Earnings Top Estimates, Sales Rise Y/Y
Microchip's (MCHP) fourth-quarter fiscal 2023 results reflect continued momentum in the mixed-signal microcontroller business.
Zacks
Apple (AAPL) Q2 Earnings Beat Estimates, Revenues Decline Y/Y
Apple's (AAPL) second-quarter fiscal 2023 results benefit from strong demand for iPhone 14 amid significant forex headwind and challenging macroenvironment conditions.
Simply Wall St.
Fewer Investors Than Expected Jumping On Enfusion, Inc. (NYSE:ENFN)
With a median price-to-sales (or "P/S") ratio of close to 4.2x in the Software industry in the United States, you could...
Zacks
Enfusion (ENFN) to Report Q1 Earnings: What's in the Offing?
Enfusion's (ENFN) first-quarter 2023 performance is expected to have benefited from healthy demand, new clients and improving margins.
Zacks
Datadog (DDOG) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
Datadog's (DDOG) first-quarter 2023 top line benefits from customers' attraction toward new innovations.
Zacks
Dolby's (DLB) Q2 Earnings & Revenues Beat Estimates, Up Y/Y
Dolby's (DLB) second-quarter fiscal 2023 performance benefits from revenue growth across all business segments and increased adoption of Dolby Atmos and Dolby Vision.
Zacks
TELUS (TU) Q1 Earnings Miss Estimates, Revenues Rise Y/Y
TELUS's (TU) first-quarter performance gains from high service revenues in TELUS technology solutions and TELUS International.
Zacks
Cirrus Logic (CRUS) Q4 Earnings Top Estimates, Down Y/Y
Cirrus Logic's (CRUS) fourth-quarter fiscal 2023 performance declines due to lower general market sales and reduced smartphone sales.
Zacks
ANSYS (ANSS) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
ANSYS's (ANSS) first-quarter performance benefits from strength in the aerospace and defense, high-tech and automotive sectors
Zacks
Watts Water (WTS) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Watts Water's (WTS) first-quarter performance improves due to momentum across APMEA and the Americas amid rising inflation.
Zacks
CDW's Q1 Earnings & Revenues Surpass Estimates, Down Y/Y
CDW's first-quarter 2023 performance is affected due to weakness across all business segments and weakening IT spending.
Zacks
Lumen (LUMN) Q1 Earnings Miss Estimates, Revenues Down Y/Y
Lumen's (LUMN) first-quarter 2023 performance is affected by the completion of the sale of its Latin America business and its 20-state ILEC business to Apollo.
Zacks
Enfusion, Inc. (ENFN) Flat As Market Sinks: What You Should Know
In the latest trading session, Enfusion, Inc. (ENFN) closed at $8.56, marking no change from the previous day.
Zacks
Enfusion, Inc. (ENFN) Q1 Earnings Preview: What's in the Cards?
Enfusion, Inc. (ENFN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
SNAP's Q1 Earnings Increase Y/Y, Revenues Miss Estimates
SNAP's first-quarter 2023 results reflect steady user growth and an increase in Snapchat+ users amid a fall in average revenues per user.
Zacks
Bears are Losing Control Over Enfusion, Inc. (ENFN), Here's Why It's a 'Buy' Now
Enfusion, Inc. (ENFN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.